Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany”

In Fig. 2c and f of our publication Schneeweiss et al. [1] we mistakenly placed wrong Kaplan Meier Plots. In the attached figure this was corrected. All other estimates concerning the survival including the regression models are correct. We apologize for the mistake.

• 1.Schneeweiss A, Ettl J, Luftner D et al. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54: 88–95.

Fig. 2. Progression-free survival (PFS) and overall survival (OS) for the total group analyzed. CDK4/6i, CDK4/6 inhibitors; ET, endocrine therapy; OS, overall survival; PFS, progression-free survival.

2a (PFS first-line setting)	2b (OS first-line setting)
2c (PFS second-line setting)	2d (OS second-line setting)
2e (PFS third-line setting)	2f (OS third-line setting)